How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

9,400 results for

Cholesterol Education Resources

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

61. The Dual Impact of Homocysteine and Cholesterol on Cognitive Functions

: June 1, 2018 Actual Study Completion Date : August 1, 2018 Resource links provided by the National Library of Medicine related topics: resources: Groups and Cohorts Go to Group/Cohort Intervention/treatment Apparently normal participants Participants are not complaining from any cognitive decline are subjected to cognitive and cholesterol and homocysteine levels assessment. Diagnostic Test: Blood sampling for total cholesterol and homocysteine and cognitive assessment by psychometric tests. all (...) for additional information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Keywords provided by MWAmeen, Assiut University: Cholesterol Dementia Homocysteine Cognitive dysfunctions Additional relevant MeSH terms: Layout table for MeSH terms Hypercholesterolemia Cognitive Dysfunction Hyperhomocysteinemia Hyperlipidemias Dyslipidemias Lipid Metabolism Disorders Metabolic Diseases Cognition Disorders Neurocognitive Disorders Mental Disorders Amino Acid Metabolism

2018 Clinical Trials

62. LDL-cholesterol Lowering Effect of a New Dietary Supplement

cholesterol increase [ Time Frame: 8 weeks ] The secondary efficacy variables were the HDL-C between the start and the end (8 weeks)of each treatment period, expressed as a percentage of the initial value Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study (...) LDL-cholesterol Lowering Effect of a New Dietary Supplement LDL-cholesterol Lowering Effect of a New Dietary Supplement - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. LDL-cholesterol Lowering Effect

2018 Clinical Trials

63. A First In Human Study to Assess CiVi007 in Subjects With an Elevated LDL-Cholesterol Level

, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered CiVi007 in Subjects With an Elevated LDL C Level Actual Study Start Date : February 7, 2018 Estimated Primary Completion Date : June 2019 Estimated Study Completion Date : January 2020 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment Experimental: Cohort A1 CiVi007 dose 1 Drug: CiVi007 cholesterol lowering drug Experimental: Cohort A2 CiVi007 dose 2 Drug (...) A First In Human Study to Assess CiVi007 in Subjects With an Elevated LDL-Cholesterol Level A First In Human Study to Assess CiVi007 in Subjects With an Elevated LDL-Cholesterol Level - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more

2018 Clinical Trials

64. The Effects of Strawberries on Blood Cholesterol.

. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years to 65 Years (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: elevated total and LDL cholesterol features of the metabolic syndrome Exclusion Criteria: previous history of adverse CVD events allergic to strawberries pregnant and/or lactating Contacts and Locations Go to Information from the National Library of Medicine To learn more about (...) The Effects of Strawberries on Blood Cholesterol. The Effects of Strawberries on Blood Cholesterol. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. The Effects of Strawberries on Blood Cholesterol

2018 Clinical Trials

65. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults Full Text available with Trip Pro

, fibrates (fenofibrate, gemfibrozil), nicotinic acid (niacin in immediate-, slow-, or extended-release form), bile acid sequestrants, ezetimibe, omega-3 fatty acids (also called marine fatty acids, including eicosapentaenoic acid alone, docosahexanoic acid alone, eicosapentaenoic acid plus docosahexanoic acid, and alpha-linolenic acid). There were no ASCVD outcomes identified for plant sterols, sterol esters, stanols, or stanol esters. A single ASCVD outcomes trial used Xuezhikang, an extract from red (...) 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults | Circulation Search Hello Guest! Login to your account Email Password Keep me logged in Search March 2019 March 2019 March 2019 March 2019 March 2019 February 2019 February 2019 February 2019 February 2019 January 2019 January 2019 January 2019 January 2019

2013 American Heart Association

66. Favorable Cardiovascular Health Is Associated With Lower Health Care Expenditures and Resource Utilization in a Large US Employee Population: The Baptist Health South Florida Employee Study. (Abstract)

Favorable Cardiovascular Health Is Associated With Lower Health Care Expenditures and Resource Utilization in a Large US Employee Population: The Baptist Health South Florida Employee Study. To examine the association of favorable cardiovascular health (CVH) status with 1-year health care expenditures and resource utilization in a large health care employee population.Employees of Baptist Health South Florida participated in a health risk assessment from January 1 through September 30, 2014 (...) . Information on dietary patterns, physical activity, blood pressure, blood glucose level, total cholesterol level, and smoking were collected. Participants were categorized into CVH profiles using the American Heart Association's ideal CVH construct as optimal (6-7 metrics), moderate (3-5 metrics), and low (0-2 metrics). Two-part econometric models were used to analyze health care expenditures.Of 9097 participants (mean ± SD age, 42.7±12.1 years), 1054 (11.6%) had optimal, 6945 (76.3%) had moderate

2017 Mayo Clinic Proceedings

67. Genetic endowments, parental resources and adult health: Evidence from the Young Finns Study. (Abstract)

studies. Socioeconomic gradients in health differ based on biomarker and resource measures. Family education is negatively related to obesity and the waist-hip ratio, and family income is negatively related to low-density lipoprotein cholesterol and triglyceride levels. Parental resources do not modify the effects of genetic endowment on adult health. However, there is evidence for gene-family income interactions for triglyceride levels, particularly among women.Copyright © 2017 Elsevier Ltd. All (...) Genetic endowments, parental resources and adult health: Evidence from the Young Finns Study. This paper uses longitudinal survey data linked to administrative registers to examine socioeconomic gradients in health, particularly whether the effects of genetic endowments interact with the socioeconomic resources of the parental household. We find that genetic risk scores contribute to adult health measured by biomarkers. This result is consistent with the findings from genome-wide association

2017 Social Science & Medicine

68. Impact of LDL-cholesterol Lowering on Platelet Activation

of LDL-cholesterol Lowering on Platelet Activation Estimated Study Start Date : January 2018 Estimated Primary Completion Date : February 1, 2020 Estimated Study Completion Date : June 1, 2020 Resource links provided by the National Library of Medicine related topics: related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Active Comparator: Evolocumab Subjects will start with placebo and will receive Evolocumab 140 mg every 14 days starting Day 14 until Day 88. Drug (...) : All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Subjects who have a clinical diagnosis of familial hypercholesterolemia (FH) Subjects who are referred to Dr. Ginsberg's Lipid Practice for treatment with PCSK9 inhibitor Subjects with LDL cholesterol levels >100 mg/dl on baseline treatment with statins and/or ezitimibe Exclusion Criteria: Children under 18 years of age Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you

2017 Clinical Trials

69. Effect of Intake of Citron(Citrus Junos Siebold ex Tanaka) Peel Extract on Blood Cholesterol.

Purpose: Prevention Official Title: A 12-week, Randomized, Double-blind, Placebo-controlled Human Trial to Evaluate the Efficacy and Safety of Citron(Citrus Junos Siebold ex Tanaka) Peel Extract on Improvement of Blood Cholesterol Actual Study Start Date : June 7, 2017 Actual Primary Completion Date : September 28, 2017 Actual Study Completion Date : September 28, 2017 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment (...) Effect of Intake of Citron(Citrus Junos Siebold ex Tanaka) Peel Extract on Blood Cholesterol. Effect of Intake of Citron(Citrus Junos Siebold ex Tanaka) Peel Extract on Blood Cholesterol. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one

2017 Clinical Trials

70. Prognostic Value of Serum Cholesterol and Triglyceride in Septic and Non Septic Patients

(ICU admission), 1, 3, and 7, 10 and 14. Study Design Go to Layout table for study information Study Type : Observational Actual Enrollment : 100 participants Observational Model: Other Time Perspective: Other Official Title: Prognostic Value of Serum Cholesterol and Triglyceride in Septic and Non Septic Patients: Randomized Double Blinded Study Actual Study Start Date : January 7, 2018 Actual Primary Completion Date : November 13, 2018 Actual Study Completion Date : December 13, 2018 Resource (...) Prognostic Value of Serum Cholesterol and Triglyceride in Septic and Non Septic Patients Prognostic Value of Serum Cholesterol and Triglyceride in Septic and Non Septic Patients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies

2017 Clinical Trials

71. the Change of Cholesterol Efflux Capacity and Coronary Artery Disease in Real Clinical Practice

tubes and stored at 4°C for less than 4 hours. The blood was then centrifuged, and serum was separated and stored at -80°C. The change of cholesterol efflux capacity, HDL-C subclasses (preβ1-HDL, HDL2, HDL3), the concentration and activity of plasma LCAT were measured. A follow-up form was designed according to the research purpose and discussed among the team members. The follow-up was performed through telephone by the trained investigators with good communication skills and knowledge (...) Start Date : April 1, 2018 Estimated Primary Completion Date : December 31, 2021 Estimated Study Completion Date : December 31, 2021 Resource links provided by the National Library of Medicine related topics: Groups and Cohorts Go to Outcome Measures Go to Primary Outcome Measures : the change of cholesterol efflux capacity [ Time Frame: before and 6-, 12-, 18-, 24- month after follow-up ] the change of cholesterol efflux capacity Secondary Outcome Measures : the change of HDL-C subclasses (preβ1

2017 Clinical Trials

72. Investigating the Lowest Threshold of Vascular Benefits From LDL Cholesterol Lowering in Patients With Stable CV Disease

Investigating the Lowest Threshold of Vascular Benefits From LDL Cholesterol Lowering in Patients With Stable CV Disease Investigating the Lowest Threshold of Vascular Benefits From LDL Cholesterol Lowering in Patients With Stable CV Disease - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum (...) number of saved studies (100). Please remove one or more studies before adding more. Investigating the Lowest Threshold of Vascular Benefits From LDL Cholesterol Lowering in Patients With Stable CV Disease (INTENSITY-HIGH) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read

2017 Clinical Trials

73. Rhodospirillum Rubrum and Cholesterol

Intervention Model: Parallel Assignment Masking: Double (Participant, Investigator) Primary Purpose: Prevention Official Title: A Proof of Concept Study to Demonstrate a Cholesterol-lowering Benefit of Oven-dried Rhodospirillum Rubrum Actual Study Start Date : June 14, 2018 Estimated Primary Completion Date : June 2019 Estimated Study Completion Date : June 2019 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment Placebo (...) Rhodospirillum Rubrum and Cholesterol Rhodospirillum Rubrum and Cholesterol - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Rhodospirillum Rubrum and Cholesterol The safety and scientific validity

2017 Clinical Trials

74. Algae and Cholesterol Absorption

in the four weeks prior to the screening and/or during the study; Use of cholesterol or lipid-lowering medications (e.g. statins, bile-acid sequestrates, cholesterol absorption inhibitors); Use of any kind of medication or a medically prescribed diet, which can interfere with the study; Use of oral antibiotics in 40 days or less prior to the start of the study; Use of food supplements that might interfere with study measurements (judged by the principal investigator) in four weeks or less prior (...) Algae and Cholesterol Absorption Algae and Cholesterol Absorption - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Algae and Cholesterol Absorption The safety and scientific validity of this study

2017 Clinical Trials

75. The Cholesterol-lowering Efficacy of Probiotic Lactobacillus Plantarum in Hypercholesterolaemic Adults

to health'. They are marketed as health or functional foods whereby they are ingested for their purported positive advantages in the digestive tract and/or systemic areas like the liver, vagina or bloodstream. The main goal of the study was to test whether probiotics can directly degrade cholesterol as well as produce metabolites that interfere with its synthesis in the liver. The effect may also be partially ascribed to an enzymatic deconjugation of bile acids. Condition or disease Intervention (...) : Prevention Official Title: Single-centre, Prospective, Randomised, Placebo-controlled, Parallel-group Design to Determine the Cholesterol-lowering Efficacy of Lactobacillus Plantarum ECGC 13110402 in Normal to Mildly Hypercholesterolaemic Adults Actual Study Start Date : January 2015 Actual Primary Completion Date : June 2015 Actual Study Completion Date : August 2015 Resource links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Arm Intervention

2017 Clinical Trials

76. EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS)

, Outcomes Assessor) Primary Purpose: Treatment Official Title: EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS) - A Randomized, Double-blind, Placebo-controlled Multicenter Study Actual Study Start Date : January 23, 2018 Estimated Primary Completion Date : June 30, 2019 Estimated Study Completion Date : September 30, 2019 Resource links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Arm (...) to atorvastatin (any dose) OR statin intolerance; Known allergy to contrast medium, heparin, aspirin, ticagrelor or prasugrel; Known sensitivity to any substances to be administered; Patients who previously received evolocumab or other PCSK9 inhibitor; Patient who received cholesterol ester transfer protein inhibitors in the past 12 months prior to screening; Treatment with systemic steroids or systemic cyclosporine in the past 3 months systemic cyclosporine, systemic steroids (eg. intravenous, intramuscular

2017 Clinical Trials

77. Cross-over Pilot Study of Blood Cholesterol Response to Dietary Saturated Fat in Patients With Autosomal Dominant Hypercholesterolemia

Cross-over Pilot Study of Blood Cholesterol Response to Dietary Saturated Fat in Patients With Autosomal Dominant Hypercholesterolemia Cross-over Pilot Study of Blood Cholesterol Response to Dietary Saturated Fat in Patients With Autosomal Dominant Hypercholesterolemia - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning (...) You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Cross-over Pilot Study of Blood Cholesterol Response to Dietary Saturated Fat in Patients With Autosomal Dominant Hypercholesterolemia The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier

2017 Clinical Trials

78. RISSCI-1 Blood Cholesterol Response Study

weeks (after diet 1), 8 weeks (after diet 2) ] Other relevant genes involved in the absorption and metabolism of dietary fat [ Time Frame: Baseline ] Polymorphic genes with potential influence on the serum LDL response to dietary saturated fat, e.g.: ATP-binding cassette proteins (cholesterol efflux proteins) ABCG5 (e.g. C1950G) ABCG8 (e.g. D19H, C1895T), functional polymorphisms in the farnesoid X receptor (FXR) and bile acid transporters (e.g. solute carrier organics anion 1B1). Fatty acid (...) : October 2017 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: No Layout table for additional information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Keywords provided by Bruce A. Griffin, University of Surrey: Dietary fat modification Lipids LDL cholesterol Dietary fatty acids Saturated fat

2017 Clinical Trials

79. An Extension Trial of Inclisiran Compared to Evolocumab in Participants With Cardiovascular Disease and High Cholesterol

, 2018 Estimated Study Completion Date : January 2022 Resource links provided by the National Library of Medicine related topics: related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: Inclisiran Participants will receive subcutaneous injections of inclisiran 300 milligrams (mg) on Day 1 and every 180 days thereafter for up to 4 years. Drug: Inclisiran Inclisiran is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting (...) An Extension Trial of Inclisiran Compared to Evolocumab in Participants With Cardiovascular Disease and High Cholesterol An Extension Trial of Inclisiran Compared to Evolocumab in Participants With Cardiovascular Disease and High Cholesterol - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum

2017 Clinical Trials

80. GPur- Luminating Oral Cholesterol Kinetics Pilot Study

Date : January 15, 2018 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment No Intervention: Control Active Comparator: Product Dietary Supplement: clinoptilolite randomized, open-label, cross-over study of control vs clinoptilolite with a washout period separating the 2 phases Outcome Measures Go to Primary Outcome Measures : Percent change in fractional cholesterol absorption in human subjects taking clinoptilolite (...) per day) Pregnancy, nursing or not taking/using contraception Hepatobiliary disorders or renal disease Plasma total cholesterol > 240mg/dl or Triglycerides > 265.5 mg/dl No plant-sterol enriched food products allowed in diet & supplements BMI > 35 Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study

2017 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>